Shots:
- Samsung Bioepis has entered into a global license, development & commercialization agreement with Sandoz for up to five biosimilars, incl. SB36 (preclinical), a biosimilar version of Entyvio (vedolizumab)
- Samsung Bioepis will handle development, manufacturing & regulatory filings, while Sandoz will lead commercialization globally (excl. China, Hong Kong, Taiwan, Macau & Republic of Korea)
- The deal builds on the prior partnership (Sep 2023) for Pyzchiva (Biosimilar, Stelara), launched in EU (Jul 2024) & US (Feb 2025), & follows their Dec 2025 deal for Epysqli (Biosimilar, Soliris) in the Middle East & Africa region
Ref: Businesswire | Image: Samsung Bioepis & Sandoz |Press Release
Related News: Alvotech and Sandoz Partner to Expand Access to Biosimilars Across Canada, Australia, & New Zealand
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
